Spexis

About Spexis

Spexis AG (SIX: SPEX) is a clinical-stage biopharmaceutical company headquartered in Allschwil, Switzerland, focused on discovering and developing macrocyclic molecules for rare diseases and cancer. The company was formed in December 2021 through the merger of the publicly listed Swiss firm Polyphor AG and the private US-based EnBiotix, Inc. The merged entity builds upon more than 25 years of research and over $400 million in cumulative investment in its macrocyclic technology platform, which targets difficult-to-drug structures.

The company's pipeline includes several clinical-stage candidates. Its product, ColiFin®, is an inhaled therapeutic for cystic fibrosis already marketed in Europe. Other key assets include Inhaled Murepavadin for Pseudomonas aeruginosa infections in cystic fibrosis patients, and Balixafortide, a CXCR4 inhibitor being evaluated for oncology indications like pancreatic cancer. The business model focuses on advancing these proprietary and in-licensed drug candidates through clinical trials to address significant unmet medical needs. Spexis seeks development, commercialization, and financial partners to advance its programs and leverages its platform to generate new therapeutic candidates.

Led by CEO Jeffrey D. Wager, M.D., the company has faced recent financial challenges, including obtaining extensions for its annual report publications and entering a definitive moratorium status as of July 2024. The company's shares on the SIX Swiss Exchange were suspended from trading in June 2024.